ReviewThe oncologist2011
Update on meningiomas.
Review in The oncologist, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
87 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Single session versus multisession stereotactic radiosurgery for the management of intracranial meningiomas: a systematic review and meta-analysis.Journal of neuro-oncology · 2023Pooled it
- The prognostic role of Ki-67/MIB-1 in meningioma: A systematic review with meta-analysis.Medicine · 2020Pooled it
- Inverse Association between Prediagnostic IgE Levels and the Risk of Brain Tumors: A Systematic Review and Meta-Analysis.BioMed research international · 2015Pooled it
- Reproductive factors in relation to risk of brain tumors in women: an updated meta-analysis of 27 independent studies.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Pooled it
- Molecular mechanisms and therapeutic targeting implications of ER/mTOR signaling axis-driven tumor progression in aggressive meningiomas.Translational oncology · 2026Article
- The 2024 Brain Tumor Segmentation Challenge Meningioma Radiotherapy (BraTS-MEN-RT) dataset.Scientific data · 2026Article
- Development and validation of a prognostic nomogram for overall survival in individuals with malignant meningiomas: a population-based study.Scientific reports · 2025Article
- Management of Aggressive Recurrent Meningioma Using a Combined Transfacial-Pterional Approach.Cureus · 2025Article
- Optimizing meningioma grading with radiomics and deep features integration, attention mechanisms, and reproducibility analysis.European journal of medical research · 2025Article
- Stereotactic Radiosurgery for Recurrent Meningioma: A Systematic Review of Risk Factors and Management Approaches.Cancers · 2025Review
- An evidence-based framework for postoperative surveillance of meningioma.Neuro-oncology practice · 2025Article
- A Case Report Depicting a Rare Neurosurgical Disease: Aggressive Meningiomatosis.Journal of clinical medicine · 2025Article
- Case Report: Advanced grade 2 meningioma withFrontiers in oncology · 2025Article
- Malignant Transformation of Meningiomas.Journal of Cancer · 2025Review
- NF2 can mediate the expression of CAMK2A in a tissue specific manner.Scientific reports · 2024Article
- Article
- Review
- Benefits of preoperative embolization before resection of a giant convexity meningioma: a case report.The Pan African medical journal · 2024Article
- The Endoscopic-Assisted Supraorbital Approach for Resection of Anterior Skull Base Meningiomas: A Large Single-Center Retrospective Surgical Study.Journal of neurological surgery. Part B, Skull base · 2023Article
- Surveillance, Epidemiology, and End Results database and propensity score matching analysis of postoperative radiotherapy for non-malignant meningioma: A retrospective cohort study.Cancer medicine · 2023Article
27 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Although meningiomas are the most common tumor in the central nervous system, their incidence, epidemiology, and clinical outcomes have historically been poorly defined. This has been attributed to their benign course, difficulty obtaining histologic diagnosis, and lack of uniform database registration. Their clinical behavior can range from a silent incidentaloma to a lethal tumor. Projections of an aging population should raise medical awareness of an expectant rise in the incidence of meningiomas. This disease increases with advancing age, has a female predilection, and exposure to ionizing radiation is associated with a higher risk for disease development. There have been minimal advances in treatment, except in radiation therapy. Although no U.S. Food and Drug Administration-approved systemic therapy exists, there are treatment options that include hydroxyurea and sandostatin. Currently, no molecularly targeted therapy has provided clinical benefit, although recurring molecular alterations are present and novel therapies are being investigated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.